Truist Financial Corp Purchases 11,617 Shares of Inogen, Inc. (NASDAQ:INGN)

Truist Financial Corp raised its position in Inogen, Inc. (NASDAQ:INGN – Get Rating) by 92.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 24,200 shares of the medical technology company’s stock after acquiring an additional 11,617 shares during the quarter. Truist Financial Corp owned approximately 0.11% of Inogen worth $587,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. US Bancorp DE lifted its holdings in Inogen by 273.0% in the first quarter. US Bancorp DE now owns 884 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 647 shares during the period. Captrust Financial Advisors increased its position in Inogen by 124.7% in the first quarter. Captrust Financial Advisors now owns 993 shares of the medical technology company’s stock worth $32,000 after buying an additional 551 shares in the last quarter. KBC Group NV purchased a new stake in Inogen in the second quarter worth about $42,000. Nisa Investment Advisors LLC increased its position in Inogen by 383.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,270 shares of the medical technology company’s stock worth $55,000 after buying an additional 1,800 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its position in Inogen by 17.2% in the second quarter. Mutual of America Capital Management LLC now owns 3,452 shares of the medical technology company’s stock worth $83,000 after buying an additional 506 shares in the last quarter. Institutional investors own 95.93% of the company’s stock.

Wall Street Analysts Forecast Growth

INGN has been the subject of a number of analyst reports. William Blair cut Inogen from an “outperform” rating to a “market perform” rating in a research report on Tuesday, January 17th. JPMorgan Chase & Co. reduced their price target on Inogen from $32.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, November 3rd. Needham & Company LLC cut their target price on Inogen from $45.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, November 2nd. Finally, StockNews.com initiated coverage on Inogen in a research report on Wednesday, October 12th. They set a “hold” rating for the company. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $29.33.

Inogen Trading Up 4.1 %

NASDAQ:INGN opened at $22.60 on Monday. Inogen, Inc. has a 12-month low of $19.08 and a 12-month high of $36.30. The stock has a 50-day moving average price of $21.58 and a 200 day moving average price of $24.27. The stock has a market capitalization of $518.01 million, a P/E ratio of -10.27 and a beta of 0.93.

Inogen (NASDAQ:INGN – Get Rating) last released its earnings results on Wednesday, November 2nd. The medical technology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.23. The firm had revenue of $105.39 million during the quarter, compared to analysts’ expectations of $97.57 million. Inogen had a negative return on equity of 11.02% and a negative net margin of 13.69%. On average, research analysts predict that Inogen, Inc. will post -1.88 earnings per share for the current fiscal year.

Inogen Profile

(Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.